<DOC>
	<DOC>NCT02797769</DOC>
	<brief_summary>This retrospective cohort study will analyze data from multiple large U.S. health insurance claims databases to compare use of tocilizumab to other biologic disease-modifying anti-rheumatic drugs (DMARDs) in real world patients with RA. Using the date of dispensing as the index date, the analysis will compute the time to first event for several cardiovascular outcomes.</brief_summary>
	<brief_title>A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>At least 1 inpatient or 2 outpatient diagnoses of RA Continuous medical/pharmacy coverage and full claims data available At least 6 months of insurance plan enrollment prior to index date Nursing home residents Human immunodeficiency virus (HIV) Malignancy Receipt of chemotherapy Endstage renal disease, dialysis, or transplant Use of rituximab Recent cardiovascular event (includes MI, stroke, ACS, or HF) within 90 days prior to index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>